ImageneBio Inc
NASDAQ:IMABiotechnology
+$0.35 today
- Market cap
- $52.00M
- Beta
- 0.72
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.02
Volume 0.00M
Average 0.35M
IMA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
ImageneBio IncNASDAQ: IMA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $10.62M (cash outflow) rose 23.2% year over year, ahead of the +8.1% change in trailing-twelve-month net income. Sequentially, it rose 53.7% from the prior quarter. Over 3 fiscal years it compounded at -8.7% a year.
Context
- Net income amounted to 6549.4% of revenue in FY2025, up 5142.7 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$17.65M (-66.3%) for the fiscal year ending Dec 2026, a slowdown from the +6.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.62M+53.7% QoQ
- Last fiscal yearDec 2025
- -$52.4M+6.4% YoY
- LTMMar 2026
- -$45.07M+8.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +23.2% | +495.8% | +472.6 pp |
| 1 year | +6.4% | -66.3% | -72.7 pp |
| 3-year CAGR | -8.7% | -33.1% | -24.4 pp |
| 5-year CAGR | -17.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (52.4M) USD
- Year-over-year change
- -6.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (52.4M) | -6.4% |
| FY2024 | 2024-12-31 | (49.23M) | +27.8% |
| FY2023 | 2023-12-31 | (68.17M) | +0.9% |
| FY2022 | 2022-12-31 | (68.77M) | -101.6% |
| FY2021 | 2021-12-31 | (34.12M) | — |
Net Income vs competitors
How IMA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +8.1% is the 4th highest of 8, against a peer median of -3.2%.
- Over three fiscal years its annual growth of -8.7% compares with a peer median of +13.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $153.6M USD | -37.4% | +17.0% | 154.2% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $87.07M USD | +21.4% | +12.6% | — |
| FY2025 | $55.48M USD | +255.0% | -21.8% | 86687.5% | |
| LTM Mar 2026 | $49.87M USD | -29.4% | -21.8% | 4987.4% | |
IMAImageneBio Inc | LTM Mar 2026 | $45.07M USD | +8.1% | -8.7% | — |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $44.1M USD | — | +41.0% | — |
| LTM Mar 2026 | €41.2M EUR | -7.9% | +14.1% | 140477.1% | |
| LTM Mar 2026 | $40.23M USD | +45.6% | +34.5% | — | |
| LTM Mar 2026 | $24.17M USD | -3.2% | -31.5% | 339.3% | |
| Peer median (excluding IMA) | — | -3.2% | +13.4% | 4987.4% | |
Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (34.12M) | (68.77M) | (68.17M) | (49.23M) | (52.4M) |
| Depreciation & Amortization | 544K | 751K | 1.02M | 490K | 328K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.18M | 7.53M | 0 | 5.3M | 15.39M |
| Change in Working Capital | (33.03M) | (15.14M) | (21.67M) | (3.98M) | (19.19M) |
| Accounts Receivables | 361K | (291K) | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | (2.87M) | (1.17M) | (2.82M) |
| Other Working Capital | (33.39M) | (14.85M) | (18.8M) | (2.81M) | (16.37M) |
| Other Non-Cash Items | 1.17M | 1.52M | 9.07M | 1.42M | 8.02M |
| Operating Cash Flow | (60.25M) | (74.11M) | (79.74M) | (46M) | (47.84M) |
| Capital Expenditures | (1.76M) | (1.43M) | (414K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (5.22M) |
| Purchases of Investments | 0 | (216.34M) | (90.05M) | (88.3M) | (10.4M) |
| Sales of Investments | 0 | 118.49M | 154.61M | 60.46M | 9.8M |
| Other Investing Activities | 0 | 0 | 0 | (7.07M) | 0 |
| Investing Cash Flow | (1.76M) | (99.28M) | 64.14M | (34.9M) | (5.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 15M |
| Common Stock Issued | 131.3M | 0 | 37.56M | 0 | 65.84M |
| Common Stock Repurchased | 0 | 0 | (663K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 582K | 1.1M | 39.09M | 0 | 54.63M |
| Financing Cash Flow | 131.74M | 1.1M | 75.98M | 0 | 135.47M |
| Effect of Forex Changes | 0 | 0 | (406K) | 0 | 604K |
| Net Change in Cash | 69.73M | (172.3M) | 59.98M | (80.91M) | 82.41M |
| Free Cash Flow | (62.01M) | (75.54M) | (80.16M) | (46M) | (47.84M) |
ImageneBio Inc
NASDAQ:IMA
Intrinsic Alpha fair value
Locked
Current Price
$4.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.